Tag: options

HONG KONG, July 11, 2025 (GLOBE NEWSWIRE) -- MultiBank Group, the world’s largest financial derivatives institution, has officially opened the waitlist for early access to its highly anticipated utility token, MBG. This marks a significant step in the company's strategy to merge traditional finance with the Web3 ecosystem.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PepGen To Contact Him Directly To Discuss Their Options

SINGAPORE, July 11, 2025 (GLOBE NEWSWIRE) -- The cryptocurrency market is in the midst of an explosive bull run, with Bitcoin recently breaking the $110,000 mark, sparking excitement and renewed interest among traders and investors globally. As the digital asset class continues to mature, BexBack Exchange is capitalizing on this surge by offering unrivaled trading conditions to both new and seasoned crypto traders.

New York City, NY, July 11, 2025 (GLOBE NEWSWIRE) --  CrazyBulk, a leading provider of legal steroid alternatives, is excited to announce its expanded line of top-rated, natural supplements designed to help athletes and fitness enthusiasts build muscle, enhance strength, and lose fat. These cutting-edge products are formulated to provide safe, effective results, mimicking the effects of anabolic steroids without the associated side effects and legal risks.

SOUTH SAN FRANCISCO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 2,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on July 8, 2025 (the “Grant Date”), in connection with the commencement of employment.

HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Advanced Wound Care Summit USA in Boston, Massachusetts, on July 15, 2025. The presentation will include recent research advances using fibroblast-based technology for indications such as wound healing and psoriasis.